What is the equity of ImmunoGen this year?
ImmunoGen has equity of 155.8 M USD this year.
ImmunoGen Equity 2025
ImmunoGen Equity
155.8 M USD
Ticker
IMGN
ISIN
US45253H1014
WKN
878613
In 2025, ImmunoGen's equity was 155.8 M USD, a 0% increase from the 0 USD equity in the previous year.
ImmunoGen Aktienanalyse
What does ImmunoGen do?
ImmunoGen Inc is a leading company in the biotechnology industry. The company was founded in 1981 as a research facility. In recent decades, ImmunoGen Inc has specialized in the development of antibody-drug conjugates (ADCs). ADCs are drugs that consist of an antibody and a cytotoxin that specifically targets tumor cells. In this way, cancer cells can be selectively destroyed without damaging surrounding tissue. ImmunoGen Inc has achieved success in recent years, particularly in the development of ADCs against serious cancers such as lung cancer or breast cancer, and it also collaborates with major pharmaceutical companies such as Roche or Bayer. The business model of ImmunoGen Inc, therefore, consists of developing innovative cancer drugs and successfully bringing them to market. Another branch of the company is the development of therapeutics for other diseases such as rheumatoid arthritis or multiple sclerosis. ImmunoGen Inc also utilizes ADCs to selectively destroy disease-specific cells in these cases. In the past, ImmunoGen Inc has successfully launched several products on the market. For example, in 2019, the cancer drug Kadcyla, manufactured by Roche and based on ImmunoGen's ADC technology, was approved by the US Food and Drug Administration (FDA) for the treatment of certain types of breast cancer. The ADC development candidate IMGN632 also shows promising results in the treatment of acute myeloid leukemia and other cancer diseases. The history of ImmunoGen Inc has also been marked by some challenges. In the early years of the company, it faced financial difficulties and sold a large number of shares to an investor in 1999. However, the company remained diligent in research and development and eventually became one of the leading biotech companies in the field of cancer research with the development of ADCs. Nevertheless, the company has also experienced setbacks in the development of products and has had to discontinue several development programs. Despite everything, ImmunoGen Inc is considered a successful company in the biotechnology industry, effectively marketing its innovative solutions in the oncology market. It is also being closely watched to see whether future ADCs will not have to undergo as long development cycles as their predecessors, which can guarantee long-term success for the company. ImmunoGen ist eines der beliebtesten Unternehmen auf Eulerpool.com.Equity Details
Analyzing ImmunoGen's Equity
ImmunoGen's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding ImmunoGen's equity is essential for assessing its financial health, stability, and value to shareholders.
Year-to-Year Comparison
Evaluating ImmunoGen's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.
Impact on Investments
ImmunoGen's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.
Interpreting Equity Fluctuations
Fluctuations in ImmunoGen’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.
Frequently Asked Questions about ImmunoGen stock
What was the equity of ImmunoGen compared to the previous year?
The equity of ImmunoGen has increased/decreased by 0% decreased compared to the previous year.
What impact does a high equity have on investors of ImmunoGen?
A high equity is advantageous for investors of ImmunoGen as it is an indicator of the company's financial stability and its ability to manage risks and challenges.
What impact does low equity have on investors of ImmunoGen?
A low equity can be a risk for investors of ImmunoGen, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.
How does an increase in equity of ImmunoGen affect the company?
An increase in equity of ImmunoGen can strengthen the company's financial position and improve its ability to make investments in the future.
How does a reduction in the equity of ImmunoGen affect the company?
A reduction in equity of ImmunoGen can affect the financial situation of the company and lead to a higher dependence on debt capital.
What are some factors that influence the equity of ImmunoGen?
Some factors that can affect the equity of ImmunoGen include profits, dividend payments, capital increases, and acquisitions.
Why is the equity of ImmunoGen so important for investors?
The equity of ImmunoGen is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.
What strategic measures can ImmunoGen take to change the equity?
To change equity, ImmunoGen can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.
How much dividend does ImmunoGen pay?
Over the past 12 months, ImmunoGen paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, ImmunoGen is expected to pay a dividend of 0 USD.
What is the dividend yield of ImmunoGen?
The current dividend yield of ImmunoGen is .
When does ImmunoGen pay dividends?
ImmunoGen pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of ImmunoGen?
ImmunoGen paid dividends every year for the past 0 years.
What is the dividend of ImmunoGen?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is ImmunoGen located?
ImmunoGen is assigned to the 'Health' sector.
Wann musste ich die Aktien von ImmunoGen kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of ImmunoGen from 1/14/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 1/14/2025.
When did ImmunoGen pay the last dividend?
The last dividend was paid out on 1/14/2025.
What was the dividend of ImmunoGen in the year 2024?
In the year 2024, ImmunoGen distributed 0 USD as dividends.
In which currency does ImmunoGen pay out the dividend?
The dividends of ImmunoGen are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von ImmunoGen
Our stock analysis for ImmunoGen Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ImmunoGen Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
